Entries by Business Wire

, , , , , , , , ,

Pivotal Phase 3 Data for Keytruda in High-Risk Early-Stage TNBC Published in the New England Journal of Medicine

Merck announced the publication of results from the Phase 3 KEYNOTE-522 trial in the Feb. 10, 2022 edition of the New England Journal of Medicine. Results showed that neoadjuvant Keytruda in combination with chemotherapy followed by adjuvant Keytruda as monotherapy, significantly prolonged event-free survival compared with neoadjuvant chemotherapy followed by adjuvant placebo in patients with high-risk early-stage triple-negative breast cancer (TNBC).

, , , , , , , , , , ,

Medable Launches Partner Network to Accelerate Innovation and Simplify Deployment of Decentralized Clinical Trials

Medable Inc., the leading software provider for patient-centered clinical trials, launched the Medable Partner Network – uniting a diverse ecosystem of technology, service, data, site, and direct-to-patient partners that work together to accelerate deployment of decentralized clinical trials.

, , , , , , , , , , ,

epocrates Doubles Down on Commercial Business in 2022, Plans to Continue Aggressive Growth Strategy in Evolving Pharmaceutical Industry

epocrates, an athenahealth Inc. company that delivers digital clinical decision support to prescribers, shared its commitment to accelerate the company’s fast-growing commercial business and further invest in and innovate its commercial product offerings, following a period of tremendous change in the pharmaceutical industry. To help enhance and broaden epocrates’ services, the company recently brought on Matt Titus – an industry veteran of 13 years – to serve as the organization’s vice president, chief commercial officer.

, , , , , , ,

Real Chemistry Appoints Andy Johnson as Chief Information Officer

Real Chemistry, a leading provider of data-driven, tech-enabled communication and marketing solutions for the healthcare sector, announced that Andy Johnson has joined the company as Chief Information Officer (CIO). Johnson’s primary responsibilities will be to drive Real Chemistry’s information strategy, strengthen organizational systems and processes to best support the company’s people and clients, and innovate new ways to connect and collaborate.

, , , , , ,

FDA Approves Prophylactic Treatment with VONVENDI for Adult Patients Living with Severe Type 3 von Willebrand Disease

The U.S. Food and Drug Administration approved Takeda Pharmaceutical Company Limited’s Vonvendi [von Willebrand factor (Recombinant)] for routine prophylaxis to reduce the frequency of bleeding episodes in patients with severe Type 3 von Willebrand disease (VWD) receiving on-demand therapy.

, , , , , , , , , , ,

FDA Approves Genentech’s Vabysmo, the First Bispecific Antibody for the Eye, to Treat Two Leading Causes of Vision Loss

The U.S. Food and Drug Administration approved Genentech’s Vabysmo (faricimab-svoa) for the treatment of wet, or neovascular, age-related macular degeneration (AMD) and diabetic macular edema (DME).

, , , , , , , , , , ,

Galvani Bioelectronics Announces World’s First Investigational Treatment of Rheumatoid Arthritis Using Splenic Nerve Stimulation

Galvani Bioelectronics, a clinical-stage company formed through a strategic partnership between GlaxoSmithKline and Verily Life Sciences in 2016 with the aim to develop targeted neuromodulation therapies, announced that the first patient with rheumatoid arthritis was treated through stimulation of the splenic nerve using the its novel bioelectronics platform.